Healion Bio - Preclinical Infectious Disease Portfolio - Ownership and Business Overview

Life ScienceCompany

Healion Bio - Preclinical Infectious Disease Portfolio Ownership

Who owns Healion Bio - Preclinical Infectious Disease Portfolio?

Healion Bio - Preclinical Infectious Disease Portfolio is owned by Tonix Pharmaceuticals Holding. It was acquired on February 2, 2023.

Healion Bio - Preclinical Infectious Disease Portfolio Business Overview

Where is Healion Bio - Preclinical Infectious Disease Portfolio headquartered?

Healion Bio - Preclinical Infectious Disease Portfolio is headquartered in Frederick, Maryland.

What sector is Healion Bio - Preclinical Infectious Disease Portfolio in?

Healion Bio - Preclinical Infectious Disease Portfolio is a life science company.

Life Science M&A Summary in 2023

Out of 60 sectors in the Mergr database, life science ranked 9 in number of deals in 2023. The largest life science acquisition in 2023 was Seagen - which was acquired by Pfizer for $43.0B.

Join Mergr to view all 198 acquisitions of life science companies in 2023, including 24 acquisitions by private equity firms, and 174 by strategics.

Healion Bio - Preclinical Infectious Disease Portfolio

Healion Bio - Preclinical Infectious Disease Portfolio

Frederick, Maryland 21704
United States,

Healion Bio - Preclinical Infectious Disease Portfolio includes a class of broad-spectrum small molecule oral antiviral drug candidates with a novel host-directed mechanism of action.


 Subscribe to unlock this and 206,813
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 199K M&A Transactions
  • 202K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 80K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.